IVOB - INVO Bioscience, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3854
+0.0070 (+1.85%)
At close: 12:28PM EDT
Stock chart is not supported by your current browser
Previous Close0.3784
Open0.3854
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3854 - 0.3890
52 Week Range0.2501 - 0.6300
Volume5,963
Avg. Volume57,140
Market Cap59.899M
Beta (3Y Monthly)-2.43
PE Ratio (TTM)N/A
EPS (TTM)-0.0230
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.10
Trade prices are not sourced from all markets
  • INVO Bioscience's INVOcell Technology Featured in IVF Exhibit at the Science Museum in London
    PR Newswire5 days ago

    INVO Bioscience's INVOcell Technology Featured in IVF Exhibit at the Science Museum in London

    SARASOTA, Fla., June 13, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company which was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, today announced that its INVOcell device is being featured in an in-vitro fertilization ("IVF") exhibit at the Science Museum in London. The main topic of the new display is the current frontiers and challenges of human reproduction, featuring the INVOcell Culture Device among other more traditional IVF procedures. Thanks to the advances in fertility treatment, including the first IVC (Intravaginal Culture) device in the world, the INVOcell Culture Device, millions more people have an innovative, cost-effective and proven new option that may result in the joy of creating a new family.

  • INVO Bioscience to Participate in the 35th Annual Meeting of the European Society of Human Reproduction and Embryology
    PR Newswire13 days ago

    INVO Bioscience to Participate in the 35th Annual Meeting of the European Society of Human Reproduction and Embryology

    SARASOTA, Fla., June 5, 2019 /PRNewswire/ -- INVO Bioscience, Inc.® (IVOB), a medical device company which was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, today announced it will participate at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology ("ESHRE") in Vienna, Austria June 23 – 26, 2019. ESHRE is the leading European-based scientific trade organization devoted to research, education and advocacy relating to all facets of human reproduction and embryology.

  • INVO Bioscience Reports First Quarter 2019 Financial Results
    PR Newswirelast month

    INVO Bioscience Reports First Quarter 2019 Financial Results

    MEDFORD, Mass. , May 15, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company which was granted FDA clearance for its Intravaginal Culture System, INVOcell™, today announced ...

  • ACCESSWIRE2 months ago

    "The Digital Economy & World Markets"

    SAN FRANCISCO, CA / ACCESSWIRE / April 30, 2019 / Vista Partners ("Vista") has published April 2019's FREE Macroeconomic & Investment Monthly Newsletter, "The Digital Economy & World Markets." ...

  • INVO Bioscience Reports Record Fourth Quarter and Year End 2018 Financial Results
    PR Newswire2 months ago

    INVO Bioscience Reports Record Fourth Quarter and Year End 2018 Financial Results

    MEDFORD, Mass., April 16, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company which was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced its fourth quarter and year end financial results for the periods ended December 31, 2018 as well as recent highlights. Closed exclusive U.S. licensing agreement with Ferring International Center S.A. the parent Company of Ferring Pharmaceuticals U.S. to commercialize the novel INVOcell™ system for use in the treatment of infertility.

  • ACCESSWIRE3 months ago

    "Bull Market Hopping?"

    SAN FRANCISCO, CA / ACCESSWIRE / March 27, 2019 / Vista Partners ("Vista") has published March 2019's FREE Macroeconomic & Investment Monthly Newsletter, "Bull Market Hopping?" Vista's ...

  • INVO Bioscience Launches Embryology Center in the Bay Area to Support Dedicated INVOcell Clinic Being Developed by Dr. Aimee, the "Egg Whisperer"
    PR Newswire3 months ago

    INVO Bioscience Launches Embryology Center in the Bay Area to Support Dedicated INVOcell Clinic Being Developed by Dr. Aimee, the "Egg Whisperer"

    MEDFORD, Mass. and SAN FRANCISCO, March 12, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), developers of the INVOcell intravaginal culture (IVC) system, today announced the launch of its first Company-owned embryology center in the Bay Area of California. The embryology center will act as the dedicated lab for famed fertility expert, Dr. Aimee D. Eyvazzadeh, MD, MPH, commonly known as the "Egg Whisperer," who will be opening a brand-new fertility treatment center dedicated to offering the INVOcell solution. Dr. Aimee's new center will be offering INVOcell, a novel fertility treatment that uses a woman's own body for the incubation of eggs and sperm during fertilization and early embryo development.

  • ACCESSWIRE4 months ago

    "On Fed's Wings" Vista Partners Publishes February 2019's Macroeconomic & Investment Monthly Newsletter

    SAN FRANSISCO, CA / ACCESSWIRE / February 27, 2019 / Vista Partners ("Vista") has published February 2019's FREE Macroeconomic & Investment Monthly Newsletter, "On Fed's Wings." Vista's ...

  • INVO Bioscience Appoints Michael J. Campbell as COO & VP of Business Development
    PR Newswire4 months ago

    INVO Bioscience Appoints Michael J. Campbell as COO & VP of Business Development

    MEDFORD, Mass. , Feb. 4, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), developers of the INVOcell intravaginal culture (IVC) system, today announced the appointment of Michael J. Campbell as ...

  • ACCESSWIRE5 months ago

    Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter

    SAN FRANSICO, CA / ACCESSWIRE / January 30, 2019 / Vista Partners ("Vista") has published January 2019's FREE Macroeconomic & Investment Monthly Newsletter, "Global Expansion Slows." ...

  • INVO Bioscience Closes Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel INVOcell™ System for Use in the Treatment of Infertility
    PR Newswire5 months ago

    INVO Bioscience Closes Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel INVOcell™ System for Use in the Treatment of Infertility

    MEDFORD, Mass., Jan. 14, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), developers of the INVOcell intravaginal culture (IVC) system, and Ferring Pharmaceuticals, a specialty biopharmaceutical group committed to helping people around the world build families and live better lives, announced today the closing of the previously announced exclusive U.S. commercialization rights agreement for INVOcell. Ferring will be responsible for all U.S. commercial activities for INVOcell. INVO Bioscience will be responsible for manufacturing and supplying the INVOcell devices to Ferring for commercial sales as well as performing a clinical study for label enhancement.

  • INVO Bioscience to Present at the LD Micro Conference
    PR Newswire7 months ago

    INVO Bioscience to Present at the LD Micro Conference

    MEDFORD, Mass., Nov. 29, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced that Katie Karloff, Chief Executive Officer, will present at the 11th Annual LD Micro Main Event investor conference at 8:30am PT on Thursday, December 6, 2018 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience.

  • Fertility Partnership of St. Louis Expands Reproductive Services with the Introduction of INVOcell
    PR Newswire7 months ago

    Fertility Partnership of St. Louis Expands Reproductive Services with the Introduction of INVOcell

    MEDFORD, Mass., Nov. 27, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced that the Fertility Partnership of St. Louis, one of the region's leading centers, has added INVOcell to the procedures it utilizes to help its patients achieve pregnancies where traditional reproductive services have succeeded. Dr. Elan Simckes, founder of the Fertility Partnership, said, "We are pleased to add INVOcell to our palette of reproductive services.

  • The Fertility Wellness Institute Becomes First Center in State of Ohio to Offer Revolutionary INVOcell Solution
    PR Newswire7 months ago

    The Fertility Wellness Institute Becomes First Center in State of Ohio to Offer Revolutionary INVOcell Solution

    MEDFORD, Mass., Nov. 16, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced that The Fertility Wellness Institute, the new fertility clinic of famed physician, Dr. NeeOo Chin, opened its doors on November 5, 2018 by offering INVOcell to its patients. The Fertility Wellness Institute will become the first center in the state of Ohio to offer the revolutionary solution to its patients. NeeOo W. Chin, MD, founder of The Fertility Wellness Institute of Ohio, said, "INVOcell represents a new and exciting approach to fertility.

  • INVO Bioscience Reports Record Third Quarter 2018 Financial Results
    PR Newswire7 months ago

    INVO Bioscience Reports Record Third Quarter 2018 Financial Results

    MEDFORD, Mass., Nov. 14, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced its Q3 2018 financial results or the quarter ended September 30, 2018 and recent highlights. Entered exclusive U.S. licensing agreement with Ferring International Center S.A. the parent Company of Ferring Pharmaceuticals U.S. to commercialize the novel INVOcell™ system for use in the treatment of infertility on November 13, 2018. Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience, commented, "Our hard work in elevating the visibility of the INVOcell within the reproductive services community nationwide is beginning to pay meaningful dividends as more clinics are adding INVOcell to their menu of services.

  • INVO Bioscience Enters Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel INVOcell™ System for Use in the Treatment of Infertility
    PR Newswire7 months ago

    INVO Bioscience Enters Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel INVOcell™ System for Use in the Treatment of Infertility

    MEDFORD, Mass. , Nov. 13, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: IVOB), developers of the INVOcell intravaginal culture (IVC) system, and Ferring Pharmaceuticals, a specialty biopharmaceutical ...

  • Indianapolis 'Top Docs' James Donahue, MD & Leo Bonaventura, MD, Welcome First Twin INVOcell Babies in the State of Indiana
    PR Newswire7 months ago

    Indianapolis 'Top Docs' James Donahue, MD & Leo Bonaventura, MD, Welcome First Twin INVOcell Babies in the State of Indiana

    MEDFORD, Mass., Nov. 8, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced Family Beginnings, PC, a leading reproductive medicine practice in Indianapolis, reported the first delivery of healthy babies in the State of Indiana utilizing the INVOcell technology. Family Beginnings, PC is operated by two of the leading advocates of the INVOcell fertility process - James Donahue, MD & Leo Bonaventura, MD, who were again recently named 'Top Docs' by Indianapolis Monthly magazine, as they have in previous years.

  • The Fertility Center of San Antonio Expands Reproductive Services with the Addition of INVOcell
    PR Newswire7 months ago

    The Fertility Center of San Antonio Expands Reproductive Services with the Addition of INVOcell

    MEDFORD, Mass., Nov. 6, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced that The Fertility Center of San Antonio, Texas, a leading reproductive services provider in central and southeast Texas, has expanded the scope of its reproductive services with the addition of INVOcell. Matthew G. Retzloff, M.D., said, "We are pleased to be working with the INVO Bioscience team to add INVOcell to our palette of reproductive services.

  • INVOcell Enables Same-Sex Couple to Both Physically Participate in the Pregnancy and Birth of Their Child
    PR Newswire8 months ago

    INVOcell Enables Same-Sex Couple to Both Physically Participate in the Pregnancy and Birth of Their Child

    MEDFORD, Mass., Oct. 31, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced a successful pregnancy where both partners of a same-sex couple were able to carry the baby in separate phases of the pregnancy – from the fertilization of the egg and development of the embryo to the birth of the child. Katie Karloff, Chief Executive Officer of INVO Bioscience, said, "We are thrilled that our INVOcell technology was instrumental in achieving a safe and successful pregnancy. Enabling both partners to physically participate in the pregnancy is a wonderful benefit of INVOcell.

  • Alabama Fertility Welcomes the First INVOcell Baby In the State of Alabama
    PR Newswire8 months ago

    Alabama Fertility Welcomes the First INVOcell Baby In the State of Alabama

    BIRMINGHAM, Ala. and MEDFORD, Mass., Oct. 30, 2018 /PRNewswire/ -- Alabama Fertility, a leading infertility practice in Birmingham, Alabama, today announced the birth of the clinic's first newborn utilizing INVOcell, the in-vivo fertilization technology from INVO Bioscience (IVOB). This marks the first baby born from this technique in the state of Alabama. INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman's body, in vivo. The simplistic INVOcell procedure can be easily performed in an appropriately trained infertility specialist's office without the need for expensive overhead.

  • INVO Bioscience Announces Two Poster Presentations at the 2018 American Society for Reproductive Medicine (ASRM) Congress & Expo
    PR Newswire8 months ago

    INVO Bioscience Announces Two Poster Presentations at the 2018 American Society for Reproductive Medicine (ASRM) Congress & Expo

    Among the findings, after 3 dIUI cycles, an Intravaginal culture (INVOcell) cycle appears to be a more cost-effective option for lesbian couples. Intravaginal culture (INVOcell) offers a significant increase in pregnancy rates compared with intrauterine insemination (IUI). MEDFORD, Mass., Oct. 18, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, today announced that two posters were presented at the 74th Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) this past week in Denver, Colorado.

  • INVO Bioscience Reports Record Second Quarter 2018 Financial Results
    PR Newswire10 months ago

    INVO Bioscience Reports Record Second Quarter 2018 Financial Results

    MEDFORD, Mass., Aug. 14, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced its Q2 2018 financial results for the quarter ended June 30, 2018 and recent highlights.

  • INVO Bioscience Announces Uplisting to OTCQB Market
    PR Newswirelast year

    INVO Bioscience Announces Uplisting to OTCQB Market

    MEDFORD, Mass., June 29, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced today that its stock has commenced trading on the OTCQB Market ("OTCQB") after successfully uplisting from the OTC Pink Market. Multiple reporting standards also give OTCQB companies the flexibility to control reporting costs and complexity, while still providing investors with a premium market for their securities. The OTCQB is recognized by the SEC as an established public market.